CytoArm Biotechnology

CytoArm Biotechnology is a clinical-stage biopharmaceutical company based in Taiwan, focused on advancing armored CAR-T cell therapies for the treatment of solid tumors and hematological malignancies. The company's core technology, the CytoArm platform, employs a modular Linker system that enables CAR-T cells to target specific tumor antigens while simultaneously delivering therapeutic payloads to the tumor microenvironment. This approach is designed to enhance the precision, safety, and potency of cell therapies by allowing for controllable activation and multi-antigen targeting. CytoArm is currently progressing several candidates through early-stage clinical development, aiming to address significant unmet needs in oncology.